Dechert: The FTC Finds that Authorized Generic Drugs Yield Procompetitive Benefits | Practical Law

Dechert: The FTC Finds that Authorized Generic Drugs Yield Procompetitive Benefits | Practical Law

This Dechert LLP memorandum discusses an FTC study on the competitive impact of authorized generics, providing strong support for the conclusion that entry by authorized generics is procompetitive because it lowers prescription drug prices without deterring generic entry.

Dechert: The FTC Finds that Authorized Generic Drugs Yield Procompetitive Benefits

by Dechert LLP
Published on 07 Sep 2011 • USA (National/Federal)
This Dechert LLP memorandum discusses an FTC study on the competitive impact of authorized generics, providing strong support for the conclusion that entry by authorized generics is procompetitive because it lowers prescription drug prices without deterring generic entry.